Search | OpenScholar

Search results

81 results found

Combination Sodium Nitrite and Hydralazine Therapy Attenuates HFpEF Severity in a "Two-Hit" Murine Model

Publication: Journal Article

LaPenna, KB., Z. Li, JE. Doiron, TE. Sharp, H. Xia, K. Moles, K. Koul, et al. 2023. “Combination Sodium Nitrite and Hydralazine Therapy Attenuates HFpEF Severity in a ‘Two-Hit’ Murine Model”. Journal of the American Heart Association.

Hydrogen Sulfide Modulates Endothelial-Mesenchymal Transition in Heart Failure

Publication: Journal Article

Li, Z., H. Xia, TE. Sharp, KB. LaPenna, A. Katsouda, JW. Elrod, J. Pfeilschifter, et al. 2023. “Hydrogen Sulfide Modulates Endothelial-Mesenchymal Transition in Heart Failure”. Circulation Research.

Reduced Hydrogen Sulfide Bioavailability Contributes to Cardiometabolic Heart Failure with Preserved Ejection Fraction.

Publication: Journal Article

Doiron, Jake E, Mahmoud H Elbatreek, Huijing Xia, Xiaoman Yu, W H Wilson Tang, Kyle B LaPenna, Thomas E Sharp, et al. 2024. “Reduced Hydrogen Sulfide Bioavailability Contributes to Cardiometabolic Heart Failure With Preserved Ejection Fraction.”. BioRxiv : The Preprint Server for Biology.

Cardiomyocyte myofilament function in common animal models of heart failure with preserved ejection fraction.

Publication: Journal Article

Jani, Vivek P, Navid Koleini, Axel J Fenwick, Thomas E Sharp, Traci T Goodchild, Joseph A Hill, David J Lefer, Anthony Cammarato, and David A Kass. 2024. “Cardiomyocyte Myofilament Function in Common Animal Models of Heart Failure With Preserved Ejection Fraction.”. Journal of Molecular and Cellular Cardiology.

Get in Touch

Page

2025 HFpEF SUMMIT REGISTRATION OPEN

News: November 18, 2024

The HFpEF Summit is a bi-annual, two-day meeting which brings together internationally recognized leaders in the areas of clinical, translational and biological studies of heart failure with preserved ejection fraction (HFpEF). This summit is focused on the latest insights and innovations for...

Early Renal Denervation Attenuates Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction.

Publication: Journal Article

Doiron, Jake E, Zhen Li, Xiaoman Yu, Kyle B LaPenna, Heather Quiriarte, Timothy D Allerton, Kashyap Koul, et al. 2024. “Early Renal Denervation Attenuates Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction.”. Journal of the American Heart Association 13 (4): e032646.

Cardiomyocyte myofilament function in common animal models of heart failure with preserved ejection fraction.

Publication: Journal Article

Jani, Vivek P, Navid Koleini, Axel J Fenwick, Thomas E Sharp, Traci T Goodchild, Joseph A Hill, David J Lefer, Anthony Cammarato, and David A Kass. 2024. “Cardiomyocyte Myofilament Function in Common Animal Models of Heart Failure With Preserved Ejection Fraction.”. Journal of Molecular and Cellular Cardiology 197: 34-39.

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

Publication: Journal Article

Duran, Jason M, Catherine A Makarewich, Danielle Trappanese, Polina Gross, Sharmeen Husain, Jonathan Dunn, Hind Lal, et al. 2014. “Sorafenib Cardiotoxicity Increases Mortality After Myocardial Infarction.”. Circulation Research 114 (11): 1700-1712.

Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.

Publication: Journal Article

Sharp, Thomas E, and Jon C George. 2014. “Stem Cell Therapy and Breast Cancer Treatment: Review of Stem Cell Research and Potential Therapeutic Impact Against Cardiotoxicities Due to Breast Cancer Treatment.”. Frontiers in Oncology 4: 299.